AbbVie's red-hot Rinvoq scores fourth FDA approval in five months

Fast and Furious, the pharma version, has a new superhero.

How else to describe the star turn of AbbVie’s Rinvoq? With an FDA approval Friday afternoon for ankylosing spondylitis, the immunology drug has collected its fourth nod in five months.